Dual-organ toxicity during treatment with nivolumab and ipilimumab in combination with chemotherapy in the first-line treatment of non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of non-small cell lung cancer (NSCLC). The combination of nivolumab and ipilimumab with two cycles of chemotherapy improves treatment efficacy; however, this combination therapy is also associated with a high incidence of adverse...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Agnieszka Dyzma-Kasprzak, Karol Kasprzak, Elżbieta Szczepaniak-Wójtowicz, Joanna Milanowska, Izabela Chmielewska, Paweł Krawczyk
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Via Medica 2026-09-01
Seri Bilgileri:	Oncology in Clinical Practice
Konular:	NSCLC immunotherapy multi-organ toxicity pneumonitis colitis
Online Erişim:	https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/101315
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!